• Amarantus BioSciences Inc., of Sunnyvale, Calif., named Robert J. Zimmerman product development advisor.
• Array BioPharma Inc., of Boulder, Colo., added John Orwin to its board.
• AtheroNova Inc., of Irvine, Calif., added Fred Knoll to its board.
• Blueprint Medicines, of Cambridge, Mass., appointed Chris Varma president and CEO, and named Daniel S. Lynch executive chairman of its board.
• Chimerix Inc., of Research Triangle Park, N.C., appointed Michelle Berrey chief medical officer.
• Cornerstone Therapeutics Inc., of Cary, N.C., appointed Alastair McEwan chief financial officer.
• Forma Therapeutics Inc., of Watertown, Mass., appointed Peter Wirth chairman of its board.
• HemoShear LLC, of Charlottesville, Va., added Mehmood Khan and Frederick W.K. Brown to its board.
• Immatics biotechnologies GmbH, of Tuebingen, Germany, appointed Peter Chambre chairman of its board.
• Insmed Inc., of Monmouth Junction, N.J., named Andrew Drechsler chief financial officer.
• Johnson & Johnson, of New Brunswick, N.J., added A. Eugene Washington it its board.
• Oncos Therapeutics Ltd., of Helsinki, Finland, named Frans Wuite president and CEO and Pekka Simula chief operating officer.
• Regulus Therapeutics Inc., of La Jolla, Calif., added Douglas E. Williams to its board.
• Sanguine BioSciences Inc., of Santa Monica, Calif., appointed Darlene Rosario to its clinical advisory board and ethics committee.
• Viralytics Ltd., of Sydney, Australia, named Malcolm McColl CEO.